RT Journal Article
SR Electronic
T1 A phase 2A trial of the safety and tolerability of increased dose rifampicin and adjunctive linezolid, with or without aspirin, for HIV-associated tuberculous meningitis (The LASER-TBM Trial)
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.07.26.22278065
DO 10.1101/2022.07.26.22278065
A1 Davis, Angharad G
A1 Wasserman, Sean
A1 Stek, Cari
A1 Maxebengula, Mpumi
A1 Liang, C. Jason
A1 Stegmann, Stephani
A1 Koekemoer, Sonya
A1 Jackson, Amanda
A1 Kadernani, Yakub
A1 Bremer, Marise
A1 Daroowala, Remy
A1 Aziz, Saalikha
A1 Goliath, Rene
A1 Sai, Louise Lai
A1 Sihoyiya, Thandi
A1 Denti, Paolo
A1 Lai, Rachel PJ
A1 Crede, Thomas
A1 Naude, Jonathan
A1 Szymanski, Patryk
A1 Vallie, Yakoob
A1 Banderker, Ismail Abbas
A1 Moosa, Muhammed S
A1 Raubenheimer, Peter
A1 Candy, Sally
A1 Offiah, Curtis
A1 Wahl, Gerda
A1 Vorster, Isak
A1 Maartens, Gary
A1 Black, John
A1 Meintjes, Graeme
A1 Wilkinson, Robert J
YR 2022
UL http://medrxiv.org/content/early/2022/07/26/2022.07.26.22278065.abstract
AB Background Drug regimens which include intensified antibiotics alongside effective anti-inflammatory therapies may improve outcomes in Tuberculous Meningitis (TBM). Safety data on their use in combination and in the context of HIV is needed to inform clinical trial design.Methods We conducted a phase 2 open-label parallel-design RCT to assess safety of high-dose rifampicin, linezolid and aspirin in HIV-associated TBM. Participants were randomised (1.4:1:1) to three treatment arms (arm 1, standard of care (SOC); arm 2 SOC + additional rifampicin (up to 35mg/kg/day)) + linezolid 1200mg/day reducing after 28/7 to 600mg/day; arm 3, as per arm 2 + aspirin 1000mg/day) for 56 days, when the primary outcome of adverse events of special interest (AESI) or death was assessed.Results 52 participants were randomised. 59% had mild disease (MRC Grade 1) vs 39% (Grade 2) vs 2% (Grade 3). 33% of participants had microbiologically-confirmed TBM; vs 41% ‘possible’ or 25% ‘probable’. AESI or death occurred in 10/16 (arm 3) vs 4/14 (arm 2) vs 6/20 (arm 1) (p=0.083). The cumulative proportion of AESI or death (Kaplan-Meier method) demonstrated worse outcomes in arm 3 vs arm 1 (p=0.04), however only one event in arm 3 was attributable to aspirin and was mild. There was no difference in efficacy (Modified Rankin Scale) at day 56 between the three arms.Conclusions High-dose rifampicin and adjunctive linezolid can safely be added to SOC in HIV-associated TBM. Larger studies are required to evaluate whether potential toxicity associated with these interventions, particularly aspirin, is outweighed by mortality or morbidity benefit.SUMMARY In this phase 2a randomised control trial we demonstrate that high-doserifampicin and adjunctive linezolid is safe in adult HIV-associated tuberculous meningitis. Larger studies are required to evaluate potential toxicity with aspirin, in relation to benefit on morbidity and mortality.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT03927313Clinical Protocols https://wellcomeopenresearch.org/articles/6-136 Funding StatementThis study and the investigators listed are supported by Wellcome, EDCTP, Department of Science and Technology (South Africa), Research Councils UK, Cancer Research UK, Meningitis Now and National Institutes of Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Approval for the trial was granted by the University of Cape Town Human Research Ethics Committee (293/2018), Walter Sisulu University Human Research Committee (012/2019) and the South African Health Products Regulatory Authority (20180622). The trial was registered on the South African National Clinical Trials Register (DOH-27-0319-6230), Pan African National Clinical Trials Register (PACTR201902921101705) and clinicaltrials.gov (NCT03927313).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript